Acromegaly Update

Acromegaly Update — Monday September 21, 2026

This week's acromegaly literature centers on long-term disease burden — cardiovascular morbidity, musculoskeletal disease, and precision-medicine treatment selection — wh

Acromegaly Update — Tuesday September 15, 2026

It's a quiet week for acromegaly-specific research — just one review paper worth flagging — but rare disease industry news was busy, headlined by Scholar Rock's first-eve

Acromegaly Update — Monday September 7, 2026

It's a thin week for acromegaly-specific research — no top-tier-journal hits, so we're covering the best next-tier evidence on GH-axis physiology, octreotide drug deliver

Acromegaly Update — Tuesday September 1, 2026

It's a quiet week for dedicated acromegaly research — no top-tier-journal hits, just a pasireotide cost-effectiveness review and a giant-adenoma case report — while the w

Acromegaly Update — Monday August 31, 2026

It's a quiet week for acromegaly-specific research — no top-tier trials, just a handful of diagnostic and mechanistic papers — while rare disease industry news brought tw

Acromegaly Update — Monday August 24, 2026

It was a quiet week for acromegaly-specific research — three observational studies refined how we monitor and support patients rather than changing treatment — while the

Acromegaly Update — Monday August 17, 2026

It's an unusually rich week for acromegaly research — five new papers spanning a first-in-human antagonist trial and two large Swedish outcomes studies — while the rare d

Acromegaly Update — Monday August 10, 2026

It's a quiet week for acromegaly-specific trial data — the research side leans mechanistic and clinical-management, headlined by a novel long-acting GH receptor antagonis

Acromegaly Update — Monday August 3, 2026

It's a quiet week for acromegaly-specific research — no trials, just incremental papers on AI-assisted detection, surgical outcomes, and pediatric gigantism — while the b

Acromegaly Update — Monday July 27, 2026

A trio of new Pituitary papers built out the real-world case for oral paltusotine in controlled acromegaly, while on the industry side a small rare-disease repurposing st

Acromegaly Update — Monday July 20, 2026

A quiet week for acromegaly research was anchored by a strong AI-diagnosis paper in JCEM, while rare disease headlines swung between a startup's ultrasound gene-therapy b

Acromegaly Update — Monday July 13, 2026

It was a quiet week for new acromegaly research, but the rare disease industry delivered its biggest story of the year — Vertex's $10 billion acquisition of Crinetics Pha

Acromegaly Update — Monday July 6, 2026

It's a thin week for acromegaly-specific research — just one mechanistic study on tumor biology — but rare disease dealmaking was busy, headlined by Ipsen's ~$800M bet on

Acromegaly Update — Monday June 29, 2026

Paltusotine's four-year open-label data confirm durable oral control of acromegaly in patients switched from injections, while the rare disease industry absorbs a landmar

Acromegaly Update — Monday June 22, 2026

A rich week in acromegaly research — new data on renal complications, a precision medicine framework, a high-risk co-secreting tumor phenotype, and cancer risk analyses —

Acromegaly Update — Monday June 15, 2026

Surgical technique innovation and a JCEM editorial from two giants of the field reshape how we think about curing GH-secreting tumors and managing cancer risk in acromega

Acromegaly Update — Monday June 8, 2026

A landmark JCEM special issue lands this week with five major reviews and original studies that collectively reset the clinical playbook for acromegaly — from emerging or

Acromegaly Update — Monday June 1, 2026

New Pituitary research this week highlights the cardiac and bone risks that persist even in treated acromegaly patients, while the rare disease industry grapples with a m

Acromegaly Update — Monday May 25, 2026

A network meta-analysis confirms that injectable somatostatin receptor ligands remain first-line in acromegaly, while new clinical data on paltusotine and pasireotide, pl

Acromegaly Update — Monday May 18, 2026

New proteomic biomarkers could sharpen acromegaly diagnosis beyond GH/IGF-1, while the rare disease industry sees a wave of FDA decisions and high-stakes M&A activity.